Buprenorphine and Naloxone Market By Type (Branded, Generics); By Formulation (Sublingual Tablets, Sublingual Films); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies / Other Distribution Channels) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
The global Buprenorphine and Naloxone Market size was estimated at USD 4,918 million in 2025 and is expected to reach USD 6,484.83 million by 2032, growing at a CAGR of 4.03% from 2025 to 2032. Demand expansion is primarily driven by rising clinical and policy focus on evidence-based opioid use disorder treatment, which is increasing diagnosis-to-treatment conversion and long-term maintenance therapy volumes across care settings. Buprenorphine and Naloxone Market momentum also benefits from expanding pharmacy access pathways and broader payer coverage for medication-assisted treatment in high-burden geographies.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Buprenorphine and Naloxone Market Size 2025
USD 4,918 million
Buprenorphine and Naloxone Market, CAGR
4.03%
Buprenorphine and Naloxone Market Size 2032
USD 6,484.83 million
Key Market Trends & Insights
North America held 57.8% share in 2025, reflecting the largest concentration of treated patient volumes and mature treatment infrastructure.
Europe accounted for 22.4% share in 2025, supported by structured addiction-care pathways and widening access to substitution therapy programs.
Generics led By Type with 51.6% share in 2025, strengthened by payer preference and multi-source supply availability.
Sublingual Tablets led By Formulation with 52.7% share in 2025, driven by broad stocking, familiarity in maintenance protocols, and cost efficiency.
Retail Pharmacies led By Distribution Channel with 45.9% share in 2025, reflecting refill-heavy demand patterns in stable maintenance therapy.
Segment Analysis
Buprenorphine and Naloxone Market segmentation reflects a balance between affordability-led access expansion and clinically driven formulation choices. By Type, generic penetration continues to rise as therapy volumes scale across outpatient settings and payers apply cost-containment tools such as step edits and preferred formularies. By Formulation, care teams typically align dosage form selection to patient stability, adherence support, and diversion-mitigation practices, which sustains meaningful demand across both tablets and films.
Channel dynamics in the Buprenorphine and Naloxone Market remain closely tied to the treatment pathway from initiation to maintenance. Retail pharmacies capture the highest share due to recurring refills and the community-based nature of long-term therapy. Hospital pharmacies maintain a strong role through emergency and inpatient encounters, discharge planning, and integrated addiction programs that connect patients to outpatient continuation therapy.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Generics accounted for the largest share of 51.6% in 2025. Generics lead because payers and public programs prioritize lower-cost equivalents to expand covered access for maintenance therapy. Generic availability across multiple dosage strengths supports switching without disrupting dose stabilization plans. Generic competition also increases procurement resilience for high-volume dispensing locations, which reinforces continued preference for multi-source products.
By Formulation Insights
Sublingual Tablets accounted for the largest share of 52.7% in 2025. Sublingual tablets lead due to wide pharmacy stocking, consistent prescribing familiarity, and cost-advantaged acquisition in many reimbursement settings. Sublingual tablets also align well with standardized dispensing workflows used for repeat refills. Sublingual tablet adoption remains supported by clinician comfort in dose titration and long-term maintenance routines.
By Distribution Channel Insights
Retail Pharmacies accounted for the largest share of 45.9% in 2025. Retail pharmacies lead because Buprenorphine and Naloxone Market demand is dominated by recurring refills for stable patients receiving ongoing maintenance therapy. Retail networks provide broad geographic reach and routine dispensing hours that support continuity of care. Retail distribution also benefits from payer network contracting and established e-prescribing workflows used in outpatient addiction treatment.
Buprenorphine and Naloxone Market Drivers
Expanding Opioid Use Disorder Treatment Adoption
Buprenorphine and Naloxone Market growth is supported by broader adoption of medication-assisted treatment across outpatient and community care settings. Healthcare systems are increasing screening, diagnosis, and referral pathways that move more patients into pharmacotherapy. Provider education and clinical guideline alignment are improving confidence in long-term maintenance approaches. Public health initiatives and program funding also strengthen continuity of care, which raises refill volumes and supports steady market expansion.
For instance, Orexo’s 24-week clinical trial (Study OX219-008) evaluating Zubsolv® (buprenorphine/naloxone sublingual tablet) for maintenance treatment of opioid dependence found that less than 1% of participants exited the study due to treatment failure, while a 15% increase in employment was recorded among study participants outcomes that directly reinforce clinical and provider confidence in long-term pharmacotherapy maintenance.
Payer Coverage and Cost-Containment Shaping Utilization
Buprenorphine and Naloxone Market demand is strongly influenced by reimbursement rules and formulary design across public and private payers. Preferred placement for lower-cost options increases utilization scale by reducing out-of-pocket barriers. Step therapy and prior authorization frameworks can standardize product selection and channel routing. Higher treatment persistence improves refill regularity, which supports recurring revenue generation. Pricing pressure also encourages broader generic uptake that expands the treated population.
Growth in Community-Based Access Channels
Buprenorphine and Naloxone Market expansion benefits from the central role of retail pharmacy dispensing in maintenance therapy. Retail access improves geographic availability and supports consistent refill schedules, which is critical for adherence. Digital prescribing and integrated care coordination reduce friction across initiation, stabilization, and continuation phases. Hospital-linked discharge workflows also improve therapy continuation after acute encounters. Improved channel access supports reduced treatment gaps and increases long-term therapy duration.
Increasing Multi-Source Supply and Portfolio Depth
Buprenorphine and Naloxone Market supply depth expands as more manufacturers broaden dosage strengths and dosage-form coverage. Multi-source supply improves procurement stability for large dispensing networks and institutional programs. Wider availability supports switching flexibility when payer rules or contracting preferences change. Manufacturing scale can reduce unit costs and increase affordability across high-volume geographies. Competitive supply dynamics also support ongoing access expansion through improved availability and distribution reliability.
For instance, Amneal Pharmaceuticals received FDA approval in February 2013 for generic buprenorphine HCl/naloxone HCl tablets entering the market as the 7th largest generic pharmaceutical company in the U.S. at the time and further expanded its buprenorphine dosage-form portfolio in April 2020 with FDA approval of a generic transdermal buprenorphine patch (generic Butrans®).
Buprenorphine and Naloxone Market Challenges
Buprenorphine and Naloxone Market participants face persistent pricing pressure as generic competition increases and payers intensify cost-containment measures. Margin compression can limit investment in differentiation, patient support programs, and supply chain redundancies. Access rules such as prior authorization and quantity limits can create discontinuities in therapy initiation and refill continuity, especially for vulnerable populations. Dispensing restrictions and operational burden can also reduce pharmacy willingness to stock broad inventories across dosage strengths.
Buprenorphine and Naloxone Market growth is also constrained by variability in provider capacity, stigma in care delivery, and uneven treatment infrastructure across regions. Workforce shortages in addiction medicine and limited integrated behavioral health pathways can reduce diagnosis-to-treatment conversion. Diversion concerns add compliance and monitoring overhead that can slow prescribing in some settings. Fragmented care transitions between hospital encounters and outpatient maintenance can also increase drop-off risk, reducing therapy persistence.
For instance, JAMA Network Open survey of 607 office-based Texas clinicians who attended an X-waiver training course found that of 126 respondents, 61 (48.4%) had obtained the waiver yet of those waivered clinicians, only 22 (36%) were actively prescribing buprenorphine, with the remaining 64% citing complexity of the waiver process, lack of professional support, and referral network gaps as persistent barriers, demonstrating that credentialing alone does not translate into active prescribing capacity.
Buprenorphine and Naloxone Market Trends and Opportunities
Buprenorphine and Naloxone Market trends include stronger integration of treatment into primary care and community health settings, which expands access beyond specialty clinics. Structured care models that combine pharmacotherapy with behavioral support improve persistence and reduce relapse risk, increasing refill continuity. Digital tools supporting prescribing, follow-up, and adherence monitoring are improving coordination across providers and pharmacies. Expansion of pharmacy-based care pathways also creates opportunities for stronger channel partnerships and improved continuity.
For instance, Bicycle Health’s technology-enabled collaborative care model reported 75% retention at 30 days and 59% retention at 90 days, while insured patients reached 86% retention at 30 days and 80% at 90 days; the company also reported a 9.5% no-show rate, about 70% of new patients seen by a buprenorphine-waivered provider on the same or next business day, and 89% of new patients receiving provider-delivered motivational interviewing
Buprenorphine and Naloxone Market opportunities are rising in regions increasing investment in addiction services and improving medication access frameworks. Product strategies that improve availability across dosage strengths and strengthen distribution resilience can win share in high-volume programs. Contracting strategies focused on payer alignment and reliable supply can strengthen formulary positioning. Patient-centric approaches that reduce friction in refills and transitions of care can increase therapy duration, supporting stable demand across channels.
Regional Insights
North America
North America (57.8% in 2025) leads the Buprenorphine and Naloxone Market due to large treated populations, mature medication-assisted treatment delivery models, and strong retail dispensing integration. High prescription volumes and established reimbursement pathways support consistent refill demand. Broad access through community pharmacies and institutional care transitions strengthens continuity of therapy. Ongoing public health focus on evidence-based opioid use disorder management sustains adoption across states and provinces.
Europe
Europe (22.4% in 2025) remains a major Buprenorphine and Naloxone Market contributor supported by structured addiction-care programs and expanding access to substitution therapies. National health systems influence product mix through formulary design and standardized care pathways. Centralized procurement and guideline-driven prescribing can support steady utilization. Continued program expansion and improved patient access frameworks sustain long-term maintenance therapy volumes.
Asia Pacific
Asia Pacific (13.1% in 2025) shows expanding Buprenorphine and Naloxone Market potential as awareness, diagnosis, and treatment infrastructure improve. Growth is supported by increasing policy attention to opioid dependence management and gradual expansion of regulated access channels. Market development varies widely by country, shaping uneven adoption across urban and rural settings. Improvements in affordability and care integration can increase long-term treatment persistence over time.
Latin America
Latin America (4.2% in 2025) represents an emerging Buprenorphine and Naloxone Market region where access is influenced by treatment capacity, reimbursement coverage, and program availability. Private-sector treatment networks play an important role in several countries, and access remains uneven across geographies. Expansion of public health programs and improved availability through retail channels can support gradual growth. Strengthening clinical pathways and supply reliability can increase sustained utilization.
Middle East & Africa
Middle East & Africa (2.5% in 2025) remains smaller in the Buprenorphine and Naloxone Market due to limited treatment infrastructure and variable access frameworks. Adoption depends on national policy, specialist capacity, and regulated dispensing pathways. Program development and improved care integration can support incremental expansion. Strengthening provider training and improving continuity of therapy across settings can raise treatment persistence in the region.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Buprenorphine and Naloxone Market competition is characterized by strong generic participation alongside branded positioning in specific protocols and patient preference segments. Key strategies include portfolio expansion across dosage strengths, reliable supply and distribution coverage, and payer contracting to secure preferred placement. Manufacturers differentiate through channel execution, competitive pricing, and operational support for high-volume dispensing environments. Competitive intensity remains high as access expansion and cost-containment continue to shape purchasing decisions.
Indivior PLC remains a central reference competitor in the Buprenorphine and Naloxone Market through branded portfolio positioning, lifecycle management activities, and commercial focus on maintaining access in key channels. Indivior PLC strategy emphasizes sustaining prescriber familiarity and supporting continuity of therapy within regulated dispensing pathways. Indivior PLC also competes through contracting discipline and channel execution designed to protect share in the presence of multi-source alternatives. Competitive pressure from generics continues to shape Indivior PLC positioning and portfolio priorities.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Indivior PLC
Dr. Reddy’s Laboratories Ltd.
Viatris / Mylan N.V.
Hikma Pharmaceuticals PLC
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Sandoz AG / Sandoz International GmbH
Alvogen
Mallinckrodt
Amneal Pharmaceuticals LLC
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Developments
In January 2025, Hikma Pharmaceuticals announced an exclusive six-year commercial partnership with Emergent BioSolutions for the sale of KLOXXADO naloxone HCl nasal spray 8 mg in the U.S. and Canada, strengthening Hikma’s position in the naloxone segment of the market.
In September 2025, Purdue Pharma expanded its partnership with MMCAP to supply buprenorphine and naloxone tablets CIII, a generic version of Suboxone, to correctional facilities for incarcerated individuals with opioid use disorder at a cost of $0.01 per tablet.
In December 2025, Orexo AB closed its transaction with Dexcel Pharma USA to acquire the full U.S. rights to Zubsolv, a buprenorphine/naloxone sublingual tablet used for opioid use disorder treatment, marking a notable acquisition in this market.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 4918 million
Revenue forecast in 2032
USD 6484.83 million
Growth rate (CAGR)
4.03% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
By Type Outlook: Branded, Generics; By Formulation Outlook: Sublingual Tablets, Sublingual Films; By Distribution Channel Outlook: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies / Other Distribution Channels
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Key companies profiled
Indivior PLC; Dr. Reddy’s Laboratories Ltd.; Viatris / Mylan N.V.; Hikma Pharmaceuticals PLC; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Sandoz AG / Sandoz International GmbH; Alvogen; Mallinckrodt; Amneal Pharmaceuticals LLC
No. of Pages
328
By Segmentation
By Type
Branded
Generics
By Formulation
Sublingual Tablets
Sublingual Films
By Distribution channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies / Other Distribution Channels
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Introduction
1.1 Report Description
1.2 Purpose of the Report
1.3 USP & Key Offerings
1.4 Key Benefits for Stakeholders
1.5 Target Audience
1.6 Report Scope
1.7 Regional Scope
Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
Executive Summary
Market Overview
4.1 Overview
4.2 Key Industry Trends
Global Buprenorphine and Naloxone Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
Market Breakup by Type
6.1 Branded
6.2 Generics
Market Breakup by Formulation
7.1 Sublingual Tablets
7.2 Sublingual Films
Market Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.2 Retail Pharmacies
8.3 Online Pharmacies / Other Distribution Channels
Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.2 Canada
9.2 Asia-Pacific
9.2.1 China
9.2.2 Japan
9.2.3 India
9.2.4 South Korea
9.2.5 Australia
9.2.6 Indonesia
9.2.7 Others
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 United Kingdom
9.3.4 Italy
9.3.5 Spain
9.3.6 Russia
9.3.7 Others
9.4 Latin America
9.4.1 Brazil
9.4.2 Mexico
9.4.3 Others
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
Porter’s Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size and forecast for the Buprenorphine and Naloxone Market?
Buprenorphine and Naloxone Market was valued at USD 4,918 million in 2025 and is projected to reach USD 6,484.83 million by 2032. The outlook reflects steady expansion in treatment volumes and ongoing maintenance therapy demand.
What is the CAGR for the Buprenorphine and Naloxone Market during 2025–2032?
Buprenorphine and Naloxone Market is expected to grow at a CAGR of 4.03% from 2025 to 2032. Growth is supported by expanding adoption of evidence-based opioid use disorder treatment pathways.
Which is the largest segment in the Buprenorphine and Naloxone Market?
Generics is the leading Type segment with 51.6% share in 2025. Generic leadership is reinforced by payer preference, affordability, and multi-source availability across channels.
What factors are driving growth in the Buprenorphine and Naloxone Market?
Buprenorphine and Naloxone Market growth is driven by rising treatment adoption, improved payer coverage, and broader access through retail dispensing networks. Care integration and continuity of therapy further support refill-heavy demand patterns.
Who are the leading companies in the Buprenorphine and Naloxone Market?
Key companies include Indivior PLC, Dr. Reddy’s Laboratories Ltd., Viatris / Mylan N.V., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd. Sandoz AG, Alvogen, Mallinckrodt, and Amneal Pharmaceuticals LLC also remain significant participants.
Which region leads the Buprenorphine and Naloxone Market?
North America leads the Buprenorphine and Naloxone Market with 57.8% share in 2025. Regional leadership reflects strong treatment infrastructure, high treated prevalence, and mature reimbursement pathways.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Irritable Bowel Syndrome with Constipation Drugs Market size was valued at USD 4,130 million in 2024 and is anticipated to reach USD 7,814.93 million by 2032, growing at a CAGR of 8.3% during the forecast period.
The Adalimumab Drugs Market is projected to grow from USD 14,947.5 million in 2025 to an estimated USD 21,229.73 million by 2032, with a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
The Global Acute Myeloid Leukemia (AML) Therapeutics Market size was valued at USD 1,933.8 million in 2018 to USD 3,349.2 million in 2024 and is anticipated to reach USD 6,823.4 million by 2032, at a CAGR of 9.33% during the forecast period
The Argatroban Market is projected to grow from USD 684.95 Million in 2024 to an estimated USD 911.10 Million by 2032, with a CAGR of 4.87% from 2024 to 2032.
The global Blood Platelets Market size was estimated at USD 6154.6 million in 2025 and is expected to reach USD 8044.68 million by 2032, growing at a CAGR of 3.9% from 2025 to 2032.
The global Biguanides Market size was estimated at USD 18.64 million in 2025 and is expected to reach USD 23.88 million by 2032, growing at a CAGR of 3.6% from 2025 to 2032.
The Alopecia Treatment / Hair Loss Market is projected to grow from USD 3657.5 million in 2025 to an estimated USD 5257.27 million by 2032, with a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.
The Alzheimer’s Diagnosis and Drugs Market is projected to grow from USD 8,136.6 million in 2025 to an estimated USD 11,487.23 million by 2032, with a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
The AI in Telemedicine Market is projected to grow from USD 26,097.5 million in 2025 to an estimated USD 114,293.5 million by 2032, with a compound annual growth rate (CAGR) of 23.50% from 2025 to 2032.
The Adult Malignant Glioma Therapeutics Market is projected to grow from USD 2687.5 million in 2025 to an estimated USD 5337.98 million by 2032, with a compound annual growth rate (CAGR) of 10.3% from 2025 to 2032.
The Acute Bacterial Skin and Skin Structure Infection Market is projected to grow from USD 2,630.06 million in 2025 to an estimated USD 4,478.33 million by 2032, with a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.
The Acute Agitation and Aggression Treatment Market is projected to grow from USD 2,656.65 million in 2025 to an estimated USD 4,210.49 million by 2032, with a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
